History
# Registration date Revision Id
2 2020-04-25, 1399/02/06 131336
1 2020-01-21, 1398/11/01 118861
Changes made to previous revision
  • Help:

    Red color represents old content. It may be empty showing addition in the new version.
    Green color represents new content. It may be empty showing deletion in the new version.

    Inline Side by side
    Added new contents, deleted old contents, contents that are not changed.
    New table contents New table contents
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    Added new contents, contents that are not changed.
    Deleted old contents, contents that are not changed.
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    New table contents New table contents
    Unchanged contents Unchanged contents
  • General information

    2018-05-22, 1397/03/01
    2019-06-22, 1398/04/01
    empty
    There was a mistake in registering the actual start time of recruitment.
    empty
    در ثبت تاریخ واقعی شروع نمونه گیری اشتباهی وجود داشت.

Protocol summary

Study aim
Evaluating the effect of oral Pantoprazole in stomach pH
Design
open-label phase 3 controlled paralleled clinical trial of 80 patients by simple randomization
Settings and conduct
ٍEighty patients aged 0-15 years will be recruited in the study regarding inclusion and exclusion criteria. The patients will be admitted to Mofid children hospital and will be randomly divided into two intervention and control groups; in the intervention group, oral pantoprazole dissolved in Bicarbonate 8.4 percent solution by 1 milligram per kilogram dose every 12 hours. In the control group, patients receive standard treatment of parenteral Pantoprazole by 1 milligram per kilogram dose every 12 hours. After 48 hours gastric pH would be measured by nasogastric tube sample. Patient will follow-up for 2 weeks.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Pediatric intensive care unit admission, Mechanical ventilation, Naso-gastric tube placement. Exclusion criteria: Pantoprazole sensitivity, Active gastrointestinal bleeding, History of gastrointestinal ulcer.
Intervention groups
ٍEighty patients aged 0-15 years will be recruited in the study regarding inclusion and exclusion criteria. The patients will be admitted to Mofid children hospital and will be randomly divided into two intervention and control groups; in the intervention group, oral pantoprazole dissolved in Bicarbonate 8.4 percent solution by 1 milligram per kilogram dose every 12 hours. In the control group, patients receive standard treatment of parenteral Pantoprazole by 1 milligram per kilogram dose every 12 hours.
Main outcome variables
Stress ulcer occurrence; Diarrhea occurrence; Pneumonia occurrence; Morbidity and mortality

General information

Reason for update
There was a mistake in registering the actual start time of recruitment.
Acronym
IRCT registration information
IRCT registration number: IRCT20120415009475N7
Registration date: 2020-01-21, 1398/11/01
Registration timing: retrospective

Last update: 2020-04-26, 1399/02/07
Update count: 1
Registration date
2020-01-21, 1398/11/01
Registrant information
Name
Bahador Mirrahimi
Name of organization / entity
Shahid Beheshti University of Medical Sciences, Faculty of Pharmacy
Country
Iran (Islamic Republic of)
Phone
+98 21 8820 0118
Email address
mirrahimi@sbmu.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2018-09-23, 1397/07/01
Expected recruitment end date
2019-09-23, 1398/07/01
Actual recruitment start date
2019-06-22, 1398/04/01
Actual recruitment end date
2019-11-22, 1398/09/01
Trial completion date
2019-11-22, 1398/09/01
Scientific title
comparison of the effectiveness of parenteral Pantoprazole with oral Pantoprazole plus bicarbonate on gastric pH in children
Public title
comparison of the parenteral and oral Pantoprazole in children
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Pediatric intensive care unit admission Mechanical ventilation Naso-gastric tube placement
Exclusion criteria:
Pantoprazole sensitivity Active gastrointestinal bleeding History of gastrointestinal ulcer
Age
From 1 month old to 15 years old
Gender
Both
Phase
3
Groups that have been masked
No information
Sample size
Target sample size: 80
Actual sample size reached: 81
Randomization (investigator's opinion)
Randomized
Randomization description
Simple randomization executed by random numbers table generated by excel program. Patients individually will be allocated to intervention and control groups by odd and even succession of numbers in the table. There is no allocation concealment.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
کمیته اخلاق دانشگاه علوم پزشکی شهید بهشتی
Street address
Sharyati Ave.,Mofid hospital
City
Tehran
Province
Tehran
Postal code
1546815514
Approval date
2019-06-10, 1398/03/20
Ethics committee reference number
IR.SBMU.PHARMACY.REC.1398.080

Health conditions studied

1

Description of health condition studied
Stress ulceration prevention
ICD-10 code
K92.81
ICD-10 code description
Gastrointestinal mucositis (ulcerative)

Primary outcomes

1

Description
Patient's stomach pH
Timepoint
48 hours after starting treatment
Method of measurement
By litmus paper

Secondary outcomes

1

Description
Diarrhea occurrence
Timepoint
During 14 day after treatment
Method of measurement
Nurse report

2

Description
Pneumonia occurrence
Timepoint
During 14 day after treatment
Method of measurement
Based on diagnosis criteria

3

Description
Morbidity and mortality
Timepoint
Until patient discharge
Method of measurement
By report

4

Description
stress ulcer occurrence
Timepoint
During 14 day after treatment
Method of measurement
gastric lavage

Intervention groups

1

Description
Intervention group: In this group patients receive oral pantoprazole dissolved in Bicarbonate 8.4 percent solution by 1 milligram per kilogram dose every 12 hours.
Category
Treatment - Drugs

2

Description
Control group: In this group patients receive standard treatment of parenteral Pantoprazole by 1 milligram per kilogram dose every 12 hours.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Mofid children's Hospital
Full name of responsible person
Bahador Mirrahimi
Street address
Mofid Children's Hospital, Mirdamad Junction, Shariaty Ave.
City
Tehran
Province
Tehran
Postal code
1546815514
Phone
+98 21 2222 7029
Email
mirrahimi@sbmu.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr. Seyed Ali Ziaee
Street address
3rd Floor, Faculty of medicine, Arabi Ave, Daneshjoo Blvd, Velenjak.
City
Tehran
Province
Tehran
Postal code
1991953381
Phone
+98 21 2243 9951
Email
mpd@sbmu.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shahid Beheshti University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr. Bahador Mirrahimi
Position
Asistant Profesor, Pharmacotherapy.
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Mofid children's Hospital, Miradmad Junction, Shariaty Ave.
City
Tehran
Province
Tehran
Postal code
1991953381
Phone
+98 21 2222 7020
Fax
Email
mirrahimi@sbmu.ac.ir
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr. Bahador Mirrahimi
Position
Asistant Profesor, Pharmacotherapy.
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Mofid children's Hospital, Miradmad Junction, Shariaty Ave.
City
Tehran
Province
Tehran
Postal code
1991953381
Phone
+98 21 2222 7020
Fax
Email
mirrahimi@sbmu.ac.ir
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr. Bahador Mirrahimi
Position
Asistant Profesor, Pharmacotherapy.
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Mofid children's Hospital, Miradmad Junction, Shariaty Ave.
City
Tehran
Province
Tehran
Postal code
1991953381
Phone
+98 21 2222 7020
Fax
Email
mirrahimi@sbmu.ac.ir
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
The main outcome will be available.
When the data will become available and for how long
Six months after publishing data.
To whom data/document is available
The data will be available per request for people working in academic institutions.
Under which criteria data/document could be used
The data will available for using in systematic review and meta-analysis.
From where data/document is obtainable
The data will be available by contacting email; mirrahimi@sbmu.ac.ir.
What processes are involved for a request to access data/document
The data will available for using in systematic review and meta-analysis.
Comments
Loading...